Search results for Jagx

Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript

Jaguar Health (JAGX) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATENov. 17, 2025, 9 a.m. ETCALL PARTICIPANTSFounder, President, and Chief Executive Officer — Lisa ConteChief Financial Officer — Carol LizakNeed a...

Jaguar Health (JAGX) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATENov. 17, 2025, 9 a.m. ETCALL PARTICIPANTSFounder, President, and Chief Executive Officer — Lisa ConteChief Financial Officer — Carol LizakNeed a...

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGX's securities continue to be listed and traded on Nasdaq

Jaguar Health Reports First Quarter 2026 Financials

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1Company cont...

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Cong...

Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus incl...

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Anno...

Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Cont...

Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners ConferenceCompany plans to file its Earnings Report on...

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Cong...

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a n...

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until...

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Fai...

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS)Jaguar has received...

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Cr...

Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331AI data mining of real world clinical and symptom manifestation i...

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Dia...

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving nerati...

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for...

Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total...

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financia...

Click here to register

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool...

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia...

Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients w...

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with li...

Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage myelofibrosis therapy.

Janux axes solid tumor T-cell engager after poor phase 1 showing

After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers to the curb.

Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time

JAFCO Group Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation

Lilly to buy startup Ajax in bid for a better JAK drug

Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.